ViewRay, Inc. (VRAY)
| Market Cap | 541.37M |
| Revenue (ttm) | 73.47M |
| Net Income (ttm) | -109.08M |
| Shares Out | 180.46M |
| EPS (ttm) | -0.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 223,804 |
| Open | 2.94 |
| Previous Close | 2.94 |
| Day's Range | 2.88 - 3.02 |
| 52-Week Range | 2.39 - 8.25 |
| Beta | 1.12 |
| Analysts | Buy |
| Price Target | 7.58 (+152.7%) |
| Earnings Date | May 5, 2022 |
About VRAY
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. m...
Financial Performance
In 2021, ViewRay's revenue was $70.12 million, an increase of 22.98% compared to the previous year's $57.02 million. Losses were -$110.05 million, 1.98% more than in 2020.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for VRAY stock is "Buy." The 12-month stock price forecast is 7.58, which is an increase of 152.67% from the latest price.
News
What Makes ViewRay (VRAY) a New Buy Stock
ViewRay (VRAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Clinical Value of MRIdian® MRI-Guided Radiation Therapy in the Treatment of Ultracentral/Central Lung Tumors Presente...
Retrospective analysis shows MRIdian's small treatment margins enabled by adaptation and real-time tracking and automated beam control may allow for ablative radiation with minimal toxicity in hard to t...
MRIdian Clinical and Research Experience Featured in Nearly 40 Abstracts at ESTRO 2022, the Leading European Radiatio...
ViewRay celebrates 10-years as the first and only company to offer real-time tissue tracking with automatic beam gating and will host a lunch symposium highlighting new MRIdian A3i features CLEVELAND ...
ViewRay (VRAY) Reports Q1 Loss, Tops Revenue Estimates
ViewRay (VRAY) delivered earnings and revenue surprises of 12.50% and 13.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ViewRay Announces First Quarter 2022 Results
CLEVELAND , May 5, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2022. First Quarter 2022 Highlights Total rev...
UCI Health Adopts ViewRay® MRIdian® MRI-Guided Radiation Therapy System
MRIdian will be the First MRI-Guided Radiation Therapy System at the UCI Chao Family Comprehensive Cancer Center facility opening in late 2023 CLEVELAND , May 3, 2022 /PRNewswire/ -- ViewRay, Inc. (NASD...
ViewRay Announces Conference Call for First Quarter 2022 Financial Results to be Held After Market on May 5, 2022
CLEVELAND, April 21, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2022 financial results. ViewRay will hold a conference call to...
University Hospital Agostino Gemelli Treats its 1,000th Patient Using MRIdian® MRI-Guided Radiation Therapy
Center Becomes First MRIdian Program in Southern Europe to Reach this Treatment Milestone CLEVELAND, March 15, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that University Hospital ...
ViewRay to Host a Virtual Clinical Data Event for Investors and Analysts on March 16, 2022
CLEVELAND, March 10, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company will host a Virtual Clinical Data Event for Investors and Analysts on Wednesday, March 16, 2022. T...
First Toxicity Results from SCIMITAR Prospective Phase II Trial Signal Favorable Toxicity Profile of Post-Prostatecto...
CLEVELAND, March 10, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced the first toxicity results from the prospective single-arm Phase II SCIMITAR trial. A secondary analysis compared t...
ViewRay Enters into Cooperation Agreement with Hudson Executive Capital
CLEVELAND, March 9, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that it has reached an agreement with Hudson Executive Capital LP ("HEC") to appoint Susan Schnabel to the ViewRay B...
Acibadem Group Purchases Second MRIdian® System for Acibadem Altunizade Hospital in Istanbul
CLEVELAND, March 3, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Acibadem Group, one of the leading private healthcare service institutions in Turkey, has purchased a secon...
ViewRay (VRAY) Reports Q4 Loss, Tops Revenue Estimates
ViewRay (VRAY) delivered earnings and revenue surprises of -6.67% and 2.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ViewRay Announces Fourth Quarter and Full Year 2021 Results
CLEVELAND, Feb. 24, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the fourth quarter and full fiscal year ended December 31, 2021. Full Year 202...
ViewRay (VRAY) Expected to Beat Earnings Estimates: Should You Buy?
ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ViewRay's MRIdian MRI-Guided Imaging System Signal Superiority For Localized Prostate Cancer
ViewRay Inc (NASDAQ: VRAY) has announced interim data from the single-center Phase 3 MIRAGE trial comparing MRIdian MRI-guided vs. CT-guided SBRT for localized prostate cancer.
Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic B...
CLEVELAND, Feb. 15, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that interim data from the single center Phase III randomized MIRAGE trial, led by UCLA, comparing MRIdian MRI-guide...
ViewRay Announces Conference Call for Fourth Quarter and Full Year 2021 Financial Results to be Held After Market on ...
CLEVELAND, Feb. 10, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its fourth quarter and full year 2021 financial results. ViewRay will hold a conf...
ViewRay® to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
CLEVELAND, Feb. 10, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Z...
University Hospital Halle (Saale) Selects ViewRay's MRIdian® System to Broaden Advanced Radiation Therapy Treatment S...
CLEVELAND, Feb. 9, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the University Hospital Halle (Saale) in Germany has purchased a MRIdian MRI-guided radiation therapy system for...
ViewRay® to Participate in the B. Riley Securities Oncology Conference
CLEVELAND, Jan. 25, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will participate in the B. Riley Securities Oncology Conference.
ViewRay Announces Preliminary Fourth Quarter and Full Year 2021 Results
CLEVELAND, Jan. 10, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2021. T...
Wall Street Analysts Predict a 38% Upside in ViewRay (VRAY): Here's What You Should Know
The consensus price target hints at a 38.4% upside potential for ViewRay (VRAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate re...
ViewRay to Participate in the 40th Annual J.P. Morgan Healthcare Conference
CLEVELAND, Dec. 23, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced its participation in the 40th Annual J.P. Morgan Healthcare Conference.
ViewRay Receives 510(k) Clearance on Next Generation of MRIdian MRI-Guided Radiation Therapy Features
CLEVELAND, Dec. 15, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the company received FDA 510(k) clearance for its next generation of MRI-guided radiation therapy features, foc...